A Phase 1 interventional study of BIA 5-1058 and Placebo in Hypertension and Chronic Heart Failure, sponsored by Bial - Portela C S.A.. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-05.
Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Hypertension with a site in Netherlands — 23 open to participants now, 32 under way, 7 of them phase 3. Hypertension · Netherlands.
Among the 152 studies in Hypertension with a site in Netherlands, this one is the 70th largest by enrollment of the 127 interventional ones that give a count, is one of 9 that started in 2011, is one of 2 in phase 1, and was the 83rd registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →23 of the 152 studies in Hypertension with a site in Netherlands are open now. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
Zuyderland Medisch Centrum · Sites in Netherlands
Ages 18+
Medtronic Vascular · Sites in Netherlands, Australia, Belgium and 6 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in Netherlands, United States, Argentina and 32 more countries
Ages 18+
Boehringer Ingelheim · Sites in Netherlands, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 50 · Phase 4 18
First in 1997; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 139 across the 127 interventional studies, 626 across the 25 observational. Of the 103 that completed or were terminated, 38 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 152 have an industry lead sponsor. The 10 most frequent:
Bial - Portela C S.A. is the lead sponsor of 136 studies on the registry; 1 is open to participants now.
Bial - Portela C S.A. has 7 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertension with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
| NCT06256991University Medical Center GroningenPotassium Correction for RAAS Optimization in Chronic Kidney Disease | 2026-12 |
| NCT07294794University of BirminghamPersonalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 152 studies in Hypertension with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses
This was a Phase 1, double blind, randomised, placebo-controlled combined single ascending dose (SAD), including food interaction (food effect, FE) analysis, and multiple ascending dose (MAD) study.
SAD: This part consisted of an eligibility screening period, one study period involving administration of single doses of BIA 5-1058 or placebo according to a randomized design, and a follow-up period. Nine sequential groups of 8 healthy young male subjects were dosed. Within each group, 6 subjects were randomised to receive BIA 5-1058 and 2 subjects were randomised to receive placebo. In this first-in-human study, the subjects participating at the lowest dose level of 5 mg were dosed according to a sentinel dosing design to ensure optimal safety. Initially, 2 subjects were dosed; 1 subject with BIA 5-1058 and 1 subject with placebo. After the safety and tolerability results of the first 24 h following dosing for the initial subjects had been found to be acceptable to the MI, the other 6 subjects of the lowest dose level were dosed.
MAD: This part consisted of an eligibility screening period, one study period involving administration of multiple doses of BIA 5-1058 or placebo once daily for 10 days, and a follow-up period. Five sequential groups of 8 healthy young male subjects were dosed.
Within each group, 6 subjects were randomised to receive BIA 5-1058 and 2 subjects were randomised to receive placebo.
The starting dose of 50 mg was chosen taking into consideration the dose range of the previous SAD sequential groups and was approved by the IEC. Escalation to the next higher dose and the determination of the next dose level was based on safety, tolerability and available PK results of the previously administered dose
FE: This part consisted of an eligibility screening period, an open-label two-way crossover study period, and a follow-up period. One group of 12 subjects received single doses of 400 mg BIA 5-1058 during 2 treatment periods, once after having fasted overnight and once after consumption of a high fat breakfast. Each treatment was separated by a period of at least 7 days. The treatment sequence was determined by randomisation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects were eligible for the study if they met all the following inclusion criteria:
Exclusion Criteria:
Subjects were excluded from participation if any of the following exclusion criteria applied
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BIA 5-1058 (5, 25 and 100 mg) tablets
Drug: BIA 5-1058
tablets, visually matching active medication
Drug: Placebo
oral administration
Also known as: Zamicastat
oral administration
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period
Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".
Time frame: Just before drug administration and twice daily until 72 h after (last) drug administration
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Multiple Ascending Dose (MAD) Period
Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".
Time frame: Just before drug administration and twice daily until 72 h after (last) drug administration
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Food Effect (FE)
Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".
Time frame: Just before drug administration and twice daily until 72 h after (last) drug administration
Study period : Date of first screening to last follow-up: 03 March 2011 - 13 January 2012;
| Milestone | Placebo | 5 mg | 25 mg | 50 mg | 100 mg | 200 mg | 400 mg | 800 mg | 1200 mg | 1600 mg | 2400 mg | 400 mg Fasted | 400 mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 18 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 6 | 6 | 0 | 0 |
| Completed | 18 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 6 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | 5 mg | 25 mg | 50 mg | 100 mg | 200 mg | 400 mg | 800 mg | 1200 mg | 1600 mg | 2400 mg | 400 mg Fasted | 400 mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 0 | 0 | 6 | 6 | 6 | 6 | 0 | 6 | 0 | 0 | 0 | 0 |
| Completed | 10 | 0 | 0 | 6 | 6 | 6 | 6 | 0 | 6 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | 5 mg | 25 mg | 50 mg | 100 mg | 200 mg | 400 mg | 800 mg | 1200 mg | 1600 mg | 2400 mg | 400 mg Fasted | 400 mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | 5 mg | 25 mg | 50 mg | 100 mg | 200 mg | 400 mg | 800 mg | 1200 mg | 1600 mg | 2400 mg | 400 mg Fasted | 400 mg Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".
| % of subject with TEAEs related to SM | Placebo | 5 mg | 25 mg | 50 mg | 100 mg | 200 mg | 400 mg | 800 mg | 1600 mg | 2400 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period | 28 | 0 | 0 | 0 | 0 | 0 | 17 | 17 | 0 | 67 |
Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".
| % of subject with TEAEs related to SM | Placebo | 50 mg | 100 mg | 200 mg | 400 mg | 1200 mg |
|---|---|---|---|---|---|---|
| Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Multiple Ascending Dose (MAD) Period | 30 | 0 | 50 | 33 | 0 | 33 |
Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".
| % of subject with TEAEs related to SM | 400 mg Fasted | 400 mg Fed |
|---|---|---|
| Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Food Effect (FE) | 0 | 17 |
Collected over Just before drug administration and twice daily until 72 h after (last) drug administration. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (SAD) | — | 0/18 (0%) | 11/18 (61.1%) |
| 5 mg (SAD) | — | 0/6 (0%) | 0/6 (0%) |
| 25 mg (SAD) | — | 0/6 (0%) | 2/6 (33.3%) |
| 50 mg (SAD) | — | 0/6 (0%) | 3/6 (50%) |
| 100 mg (SAD) | — | 0/6 (0%) | 2/6 (33.3%) |
| 200 mg (SAD) | — | 0/6 (0%) | 4/6 (66.7%) |
| 400 mg (SAD) | — | 0/6 (0%) | 4/6 (66.7%) |
| 800 mg (SAD) | — | 0/6 (0%) | 3/6 (50%) |
| 1600 mg (SAD) | — | 0/6 (0%) | 1/6 (16.7%) |
| 2400 mg (SAD) | — | 0/6 (0%) | 4/6 (66.7%) |
| 400 mg Fasted (FE Period) | — | 0/12 (0%) | 3/12 (25%) |
| 400 mg Fed (FE Period) | — | 0/12 (0%) | 5/12 (41.7%) |
| Placebo (MAD Period) | — | 0/10 (0%) | 8/10 (80%) |
| 50 mg (MAD Period) | — | 0/6 (0%) | 5/6 (83.3%) |
| 100 mg (MAD Period) | — | 0/6 (0%) | 3/6 (50%) |
| 200 mg (MAD Period) | — | 0/6 (0%) | 5/6 (83.3%) |
| 400 mg (MAD Period) | — | 0/6 (0%) | 3/6 (50%) |
| 1200 mg (MAD Period) | — | 0/6 (0%) | 6/6 (100%) |
| Event | Placebo (SAD) | 5 mg (SAD) | 25 mg (SAD) | 50 mg (SAD) | 100 mg (SAD) | 200 mg (SAD) | 400 mg (SAD) | 800 mg (SAD) | 1600 mg (SAD) | 2400 mg (SAD) | 400 mg Fasted (FE Period) | 400 mg Fed (FE Period) | Placebo (MAD Period) | 50 mg (MAD Period) | 100 mg (MAD Period) | 200 mg (MAD Period) | 400 mg (MAD Period) | 1200 mg (MAD Period) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| headacheNervous system disorders | 4/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 3/6 | 0/12 | 0/12 | 3/10 | 2/6 | 0/6 | 1/6 | 0/6 | 5/6 |
| fatigueGeneral disorders | 0/18 | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 1/10 | 0/6 | 2/6 | 4/6 | 0/6 | 0/6 |
| nauseaGastrointestinal disorders | 0/18 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/12 | 0/12 | 0/10 | 2/6 | 0/6 | 0/6 | 0/6 | 3/6 |
| abdominal painGastrointestinal disorders | 0/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 1/12 | 1/10 | 1/6 | 0/6 | 0/6 | 0/6 | 3/6 |
| diarrhoeaGastrointestinal disorders | 0/18 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 1/6 | 1/6 | 1/6 | 0/6 | 0/12 | 1/12 | 0/10 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| application site irritationGeneral disorders | 1/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/10 | 0/6 | 0/6 | 2/6 | 0/6 | 1/6 |
| dizzinessNervous system disorders | 1/18 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 | 2/6 | 0/12 | 0/12 | 1/10 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 |
| dizziness posturalNervous system disorders | 0/18 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 1/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| catheter site related inflammationGeneral disorders | 0/18 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/10 | 0/6 | 0/6 | 2/6 | 0/6 | 1/6 |
| catheter site related reactionGeneral disorders | 2/18 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/12 | 1/12 | 2/10 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Age, Categorical(Participants) | Single Ascending Dose (SAD) | Multiple Ascending Dose (MAD) | Food Interaction (Food Effect, FE) Analysis | Total |
|---|---|---|---|---|
| <=18 years | 0 | 2 | 0 | 2 |
| Between 18 and 65 years | 72 | 38 | 12 | 122 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Single Ascending Dose (SAD) | Multiple Ascending Dose (MAD) | Food Interaction (Food Effect, FE) Analysis | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 72 | 40 | 12 | 124 |
The record gives a start of Mar 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zamicastat